NCT02909972View on ClinicalTrials.gov

Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

August 31, 2019

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

ALRN-6924

Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.

DRUG

ALRN-6924 in combination with cytarabine

Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.

Trial Locations (6)

10461

The Bronx

29605

Greenville

33612

Tampa

37203

Nashville

80218

Denver

97239-3098

Portland

Sponsors
All Listed Sponsors
lead

Aileron Therapeutics, Inc.

INDUSTRY

NCT02909972 - Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter